Abstract Tumor angiogenesis is a process that requires migration, proliferation, and differentiation of endothelial cells. We hypothesized that decrease in pancreatic tumor growth due to inhibition of Src activity is associated with the inability of Src kinase to trigger a network of such signaling processes, which finally leads to endothelial cell death and angiogenesis-restricted tumor dormancy. The therapeutic efficacy of Src kinase inhibitor AZM475271 was tested in nude mice orthotopically xenografted with L3.6pl pancreatic carcinoma cells. No liver metastases and peritoneal carcinosis were detected and a significant effect on the average pancreatic tumor burden was observed following treatment with AZM475271, which in turn correlated with a decrease in cell proliferation and an increase in apoptotic endothelial cells. AZM475271 was shown to significantly inhibit migration of human umbilical vein endothelial cells in an in vitro Boyden Chamber cell migration assay. In a rat aortic ring assay we could demonstrate as well inhibition of endothelial cell migration and sprouting following therapy with Src kinase inhibitor at similar doses. The most conclusive anti-angiogenic activity of AZM475271 was demonstrated in vivo (mouse corneal micropocket assay) by showing a marked inhibition of basic fibroblast growth factor-induced neovascularization in response to systemic administration of AZM475271. Furthermore, we could show reduced proliferation of HUVECs determined with the TACS MTT Cell Viability Assay Kit. The blockade of Src kinase significantly reduced the level of VEGF in L3.6pl medium, the effect which was found also in the cell culture supernate from HUVECs. Inhibition of Src kinase by AZM475271 also showed prevention of survival signaling from VEGF and EGF receptors. Treatment with AZM475271 resulted in VEGF -dependent inhibition of tyrosine phosphorylation of FAK. HUVECs were also examined using propidium iodide staining for cell cycle analysis by FACS. Inhibition of Src kinase promoted HUVEC apoptosis in a dosedependent manner. Taken together, our results suggest that the Src kinase inhibitor AZM475271, in addition to its effects on tumor cells, suppresses tumor growth and metastasis in vitro and in vivo potentially also by antiangiogenic mechanisms.
Introduction
Tumor angiogenesis is the process leading to the formation of blood vessels within a tumor and plays a key role in cancer cell survival in local tumor growth and in the development of distant metastases [1, 2] . A growing tumor may switch to the angiogenic phenotype, induce the formation of new capillaries, and start to invade the surrounding tissue. The ''angiogenic switch'' depends on a net balance of positive and negative angiogenic factors in the tumor. Thus, the angiogenic phenotype may result from the production of growth factors, such as basic fibroblast growth factor and vascular endothelial growth factor, by tumor cells and/or the down-regulation of negative modulators, like thrombospondin-1, in tissues with a quiescent vasculature [3] .
Certain growth factors and cytokines, including bFGF, interleukin 8, and TGF-a secreted by many different cancer cells have been identified as positive regulators of angiogenesis stimulating endothelial cell growth through paracrine mechanisms [4] [5] [6] . Consequently, inhibition of growth factor production or ligand-induced activation of growth factor receptor represents a promising strategy for the development of anticancer therapies. However, since tumor cells express a variety of different growth factors, proangiogenic agents and inducers of cell survival, selective monotherapy aimed to inhibit one of them is not able to completely prevent the development of tumor vasculature. Moreover, tumor cells, due to their genetic instability, may switch from the production of one proangiogenic factor to another.
Several oncogenes and their intracellular protein products such as src, v-ras, K-ras, v-raf, fos and v-yes induce the up-regulation of angiogenic factors like VEGF and PDGF and increase the production of cytokines and proteolytic enzymes [7] [8] [9] [10] [11] [12] .
In this respect, targeting intracellular proteins that are involved both in tumor growth and in tumor angiogenesis might be a promising approach in cancer therapy.
Src family kinases regulate multiple cellular processes including proliferation and oncogenesis. It has been recently reported that Src protein levels and Src kinase activity are significantly elevated in human breast cancers [13, 14] , colon cancers [15] [16] [17] , and pancreatic cancers [18, 19] . Furthermore, activation of Src by growth factors and growth factor receptors, such as EGF(R), PDGF(R), and HER2/Neu, has been shown to promote cell proliferation [20] [21] [22] [23] [24] . The biological importance of Src in the VEGF-dependent angiogenic system was published in a report by Eliceiri and collaborators [25] . A critical study of Mukhadopathyay [7] demonstrated that Src, but not its family members, was critical to hypoxia-induced expression of vascular endothelial growth factor in fibroblasts. Essentially, it has been estimated that not only hypoxiainducible factor (as was thought before) plays an important role in VEGF activation but the Endothelial PAS domain protein-1 (EPAS-1) as well. An investigation of human lung carcinoma cells revealed that Src kinase inhibition resulted in blockade of EPAS-1 expression and inactivation of the VEGF gene [26] . Indeed, recent clinical trial suggested that pancreatic cancer is highly angiogenesis dependent and a high microvessel density within pancreatic tumors is a prognostic factor for early disease progression [27] [28] [29] . Furthermore, clinical data indicate that expression of proangiogenic factors such as VEGF, EGF, and thymidine phosphorylase positively correlate with a high pancreatic tumor relapse rate and shorter patient survival [27, 29, 30] .
The purpose of this study was to determine whether inhibition of Src tyrosine kinase and its effects on pancreatic tumor growth is based in part on an anti-angiogenic effect, since the potential role of Src as a key factor for the ''angiogenic switch'' in pancreatic cancer has not been evaluated so far. To investigate the hypothesis that blockage of Src kinase function may inhibit pancreatic tumor growth, angiogenesis, and metastasis, we conducted invivo experiments examining the effects of a novel orally available Src kinase inhibitor AZM475271 in an orthotopic human pancreatic carcinoma model in nude mice [31] .
Our results support the hypothesis that inhibition of the Src tyrosine kinase leads to down-regulation of pancreatic tumor growth and metastasis in part by blockade of tumor angiogenesis.
Materials and methods

Drugs
AZM475271 was synthesized and kindly provided by AstraZeneca Pharmaceuticals (Macclesfield, UK). For in vivo administration, AZM475271 was dissolved in Tween 20 diluted 1:100 in NaCl, for in vitro applications the AZM475271 stock was prepared in DMSO. 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2, Calbiochem, San Diego, CA, USA) is a potent and selective inhibitor of the Src family of tyrosine kinases that is similar to PP1. For in vitro studies was used as a comparable chemotherapeutic agent.
Mice and cell lines
Male immunodeficient Balb/c nu/nu and male C57BL6 mice were purchased from Charles River Laboratories (Sulzfeld, Germany). Animal procedures were approved by the regional authorities. The highly metastatic human pancreatic cancer cell line L3.6pl [31] was maintained in Dulbecco's Minimal Essential Medium, supplemented with 10% fetal bovine serum (Biochrom AG, Berlin, Germany). Human umbilical vein endothelial cells (HUVECs) were purchased from PromoCell (Heidelberg, Germany) and were maintained in Falcon ''surface-modified,'' polystyrene flasks with endothelial cell growth Medium (PromoCell) containing 2% FBS.
Orthotopic pancreatic tumor model L3.6pl human pancreatic cancer cells were injected orthotopically as described previously [31] . Briefly, a small left abdominal flank incision was made and the spleen was exteriorized. Tumor cells (8 · 10 5 in 40 ll saline) were injected into the subcapsular region of the pancreas just beneath the spleen. Seven days after implantation of tumor cells, mice were randomly assigned to one of the following groups of 5-9 mice each: (1) daily intragastric administration of Src tyrosine kinase inhibitor AZM475271 at a dose of 25 mg/kg; (2) daily intragastric vehicle solution for AZM475271 (Tween 20 diluted 1:100 in NaCl). The animals were sacrificed 32 days after the initiation of treatment, when >50% of the control animals had become moribund. The tumor volume was then calculated using the formula V = p / 6 (a · b · c), where a, b, and c represent the length, width, and height of the mass, respectively. Tumor lesions were harvested, some were fixed in 10% buffered formalin and embedded in paraffin, and some were embedded in optimum cutting temperature (OCT) compound (Miles, Inc., Elkhart, IN), snap-frozen in liquid nitrogen, and stored at -70°C.
Immunohistochemical analyses
Evaluation of cell proliferation was performed using Ki-67-specific polyclonal rabbit anti-human antibody (Zymed, San Diego, CA). Tissues were embedded in paraffin and 4-6 lm sections were prepared and mounted on positively charged superfrost slides (Menzel-Glaeser, Braunschweig, Germany). Sections were dried overnight, deparaffinized in xylene and incubated in 100%, 95% and 80% ethanol (v/v in distilled water), before rehydrating in PBS. Ki-67 antigen retrieval was achieved by microwaving tissue sections for 15 min at 750 W. After cooling down, the slides were rinsed with PBS, and non-specific binding sites were blocked with 5% bovine serum albumin (BSA) in PBS. After another washing step with PBS, the primary antibody (1:75; Zymed, San Diego, CA), a polyclonal rabbit antihuman antibody against Ki-67, was applied, and the slides were incubated for 2 h at room temperature. The samples were then incubated with biotinylated goat anti-rabbit (Vector Laboratories, Burlingame, CA) secondary antibody (1:200) for 1 h at room temperature, followed by incubation with an avidin-biotinylated horseradish peroxidase (HRP) complex from an ABC kit (Vector Laboratories, CA). Sections were examined microscopically and the average number of cells staining positively for Ki-67 per high-power field (0.159 mm 2 ) was counted at 100· magnification.
Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) staining was performed using a commercially available apoptosis detection kit (DeadEnd Fluorometric TUNEL System, Promega, Madison, WI). CD31 staining for microvessel density was performed as described previously [32] .
Cell proliferation assay
For an assessment of AZM475271 activity directed against cultured HUVE cells, we used an in vitro TACS MTT Cell Proliferation and Viability Assay Kit (R&D Systems, Minneapolis, MN, USA). Briefly, 15 · 10 3 cells/well were plated in 96-well plates in complete medium. After 24 h of attachment, cells were treated with AZM475271 (1-25 lmol/l), and the plates were incubated for another 72 h. Cells were washed with phosphate-buffered saline (PBS), the MTT reagent was added according to the manufacturer's recommendations, and absorbance was measured at 570 nm. The IC 50 was defined as the drug concentration that causes a 50% inhibition of cell proliferation. All experiments were replicated thrice.
Cell proliferation assays were performed to examine in vitro inhibition of VEGF and EGF-induced HUVEC growth. The TACS MTT Cell Proliferation and Viability Assay Kit was used as described above. Human recombinant VEGF 165 (R&D Systems, Wiesbaden, Germany) or human recombinant EGF (R&D Systems, Wiesbaden, Germany) at concentrations of 25 ng/ml in serum-reduced Endothelial Cell Basal Medium (0.5% Fetal Calf Serum) were used. All experiments were replicated at least three times.
In vitro angiogenesis: rat aortic ring assay Angiogenesis was studied by culturing aortic explants in three-dimensional matrix gels according to the procedure of Nikosia and Ottineri [33] . Thoracic aortas were removed from 6-to 8-week-old male ACI rats (Harlan Winkelmann) and immediately transferred to a culture dish containing cold serum-free Dulbecco's Minimal Essential Medium (D-MEM, Gibco, Invitrogen). The peri-aortic tissue was carefully removed with fine microdissecting forceps and scissors, paying special attention not to damage the aortic wall. One-mm-long aortic slices (approximately 15 per one aorta) were sectioned and extensively rinsed in five consecutive washing steps with D-MEM. Ring-shaped explants of the aorta were then embedded on Matrigelcoated 24-well plates (Becton Dickinson Labware, NJ). HEPES-buffered D-MEM containing AZM475271 in different concentrations was added and the plates were incubated at 37°C, 5% CO 2 , for 4 days. Fresh medium with respective additives was reintroduced into the cultures on day 2. The rings were examined by phase contrast microscopy with a Zeiss Axiotech Vario microscope (Goettingen, Germany) at 10· magnification. An estimation of the length of the capillary was performed by measuring the distance from the aortic explants to the approximate mean point of capillary. The length of the capillary was measured using AxioVision software (Zeiss).
In vivo angiogenesis: mouse corneal micropocket assay Corneal micropockets were created in C57BL6 mice with a modified von Graefe cataract knife. A micropellet (0.35 · 0.35 mm 2 ) of sucrose aluminum sulfate (SigmaAldrich, Steinheim, Germany) coated with Hydron polymer (Sigma-Aldrich, Steinheim, Germany) (10 ll of 12% Hydron in ethanol) containing approximately 80 ng of recombinant human fibroblast growth factor (R&D Systems, Wiesbaden, Germany) was implanted into each corneal pocket, as described [34] . Control animals were implanted with pellets containing no growth factor only PBS. The pellet was positioned 1.2-1.4 mm from the corneal limbus. After implantation, erythromycin/ophthalmic ointment was applied to each eye. AZM475271 was administered by oral feeding at a dose of 25 mg/kg daily for 5 days beginning from the first postoperative day. The controls received vehicle only. The maximal vessel length and clock hours of circumferential neovascularization were measured on the sixth day after corneal implantation. The length of new vessels in the cornea was measured from the inside margin of vessels around the limbus to the tip of the longest neovascular sprout. The contiguous circumferential zone of neovascularization was measured as clock hours (length of the limbal vessel showing sprouts) with a 360°reticule (where 30°of arc equals 1 clock hour and 1 clock hour further corresponds to 1 mm limbal vessel length). Experiments were repeated twice.
Western blotting
Confluent HUVECs were incubated for 6 h in serum-reduced Endothelial Cell Basal Medium (0.5% Fetal Calf Serum was used) before addition of AZM475271 for a further 4 h. After treatment the cells were stimulated by 20 ng/ml VEGF 165 for 20 min and then lysed in 1 ml of lysis buffer containing 20 mM Tris-HCl, pH 8.0, 2 mM EDTA, 17 mM NaCl, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 10% glycerol, and 1% Triton X-100. Equal amounts of protein extract were separated on SDS-polyacrylamide gel electrophoresis (SDS-polyacrylamide gel at concentration of 10% was used), transferred to a PVDF membrane Hybond P by semi-dry method, and probed with anti-FAK antibody (Cell Signaling Technology, Inc.) appropriately diluted in 5% BSA in TTBS. Primary antibody binding was detected with a goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (Amersham, Freiburg, Germany), in an enhanced chemiluminescence Western blotting system (Amersham).
In vitro Src kinase inhibition test
A poly (Glu, Tyr) 4:1 random copolymer (Sigma-Aldrich, Steinheim, Germany) was used as the tyrosine-containing substrate. This is stored as a 10 mg/ml stock solution in PBS at 20°C and diluted 1:200 with PBS to coat 96-well plates (100 ll/well). Substrate was plated the day before the assay, and the plates were covered with adhesive seals and stored overnight at 4°C. On the day of the assay, the substrate solution was discarded, and the plates were then incubated with 120 ll/well of 5% BSA in PBS for 10 min. The plates were then washed once with PBS containing 0.05% (v/v) Tween 20 (PBST) and incubated with 50 mmol/l HEPES (pH 7.4) at 100 ll/well until the next stage. Confluent HUVECs or L3.6pl were treated with different concentrations of AZM475271 and PP2. After 4 h cells were washed and lysed in 1 ml of lysis buffer containing 20 mM Tris-HCl, pH 8.0, 2 mM EDTA, 17 mM NaCl, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 10% glycerol, and 1% Triton X-100. Lysates were clarified by centrifugation at 15,000g for 10 min and active Src was then precipitated using 15 lg of v-Src (Ab-1) monoclonal antibody (Oncogene Research Products, San Diego, CA) pre-adsorbed to 50 ll of protein G-sepharose (Amersham, UK). The immune complexes containing precipitated Src were washed thrice in 1 ml of lysis buffer and used in kinase reaction as an active Src kinase. Solutions of 80 lmol/l ATP in 80 mmol/l MgCl 2 and 80 mmol/l MgCl 2 alone (negative controls) were prepared. The HEPES was discarded from the substrate plates and the following additions were now made in this order: 25 ll/well ATP/ MgCl 2 or MgCl 2 alone; 50 ll/well beads to start the reaction. The reaction time allowed was 30 min at room temperature on a plate shaker. The assay was stopped by washing the plates four times with PBST (150 ll/well). Detection of the resultant tyrosine phosphorylation was facilitated by the addition of an anti-phospho-tyrosine monoclonal antibody conjugated to HRP (anti-pY/HRP, Santa Cruz Biotechnology, Santa Cruz, CA); this was diluted 1:5,000 in PBST + 0.5% BSA + 0.1 mmol/l sodium orthovanadate, added at 100 ll/well, and incubated for 1 h. The plates were again washed (six times). One tablet of the HRP substrate TMB (Sigma-Aldrich) was dissolved in 100 ll of DMSO and added per 10 ml of phosphate citrate buffer with sodium perborate (Sigma-Aldrich, Germany). TMB substrate solution (100 ll/well) was added. After 5 min of color development, the reaction was stopped by the addition of 50 ll/well 0.8 mol/l H 2 SO 4 . Control and blank wells were included on all plates containing compound diluent and MgCl 2 solution with and without ATP, respectively, to determine the dynamic range of the assay. The in vitro VEGF-R2 kinase inhibition assay determines the ability of AZM475271 to inhibit VEGF-R2 kinase activity and has been used as a selectivity screen. The method was performed as reported previously [35] .
Determination of human vascular endothelial growth factor concentrations in cell culture supernates
The level of VEGF was measured in cell culture supernates collected on day 0, 2, and 4 from L3.6pl or HUVE cells following treatment with Src kinase inhibitor AZM475271 at different concentrations (0.1, 1 lM). The assay was performed according to the manufacturer's recommendations. All experiments were replicated thrice.
Determination of apoptotic cells by FACS analysis via propidium iodide staining
HUVECs were plated into T75 flasks (Nunc Brand Products, Denmark) and treated with different concentrations of AZM475271. After 12 h, cells were collected and suspended in a Nicoletti buffer (0.1% sodium citrate, pH 7.4, 0.1% Triton X-100, and 50 lg/ml propidium iodide). DNA content present in the resulting nuclei was determined on a fluorescence-activated cell sorter (FACS, Becton Dickinson). Experiments were repeated thrice.
Cell migration assay
Migration of HUVECs was assessed using a modified Boyden chamber assay. HUVECs (10 5 cells per well) were seeded into the upper well of a chamber system (Becton Dickinson Falcon cell culture insert; BD Biosciences, Heidelberg, Germany) on a human fibronectin-coated (Sigma-Aldrich Chemicals, Deisenhofen, Germany) polyethylene terephthalate membrane with 8-lm pores. Human recombinant VEGF 165 (R&D Systems, Wiesbaden, Germany) was added as a chemo-attractant into the lower well at 20 ng/ml. Inhibition of VEGF-induced chemotaxis was assessed after including AZM475271 at relevant doses. Migration through the membrane was determined after 4 h of incubation at 37°C by fixing, staining with hematoxylin and eosin, and counting the migrated cells in five random fields at 100· magnification. The average of triplicate inserts from three representative experiments was obtained.
Statistical analysis
Pancreatic tumor weight, body weight, and quantification of Ki67, TUNEL, and CD31 were compared using one-way ANOVA with a Student-Newman-Keuls multiple comparison test (Microcal Origin, version 6.0, Microcal Software, MA, USA). The relative rates of liver and lymph node metastases within groups were compared by Fisher's exact test. Significance was taken as P < 0.05. Results of the ELISA tests, proliferation assays, migration, corneal micropocket, and aortic ring assays were analyzed using the paired Student's t-test (Microcal Origin, version 6.0, Microcal Software, MA, USA) with P < 0.05 considered to be significant.
Results
In vitro enzyme inhibition in HUVE and L3.6pl cells AZM475271 is a potent inhibitor of the tyrosine kinase activity of recombinant, active Src. The ability of AZM475271 to inhibit the phosphorylation of Src kinase and receptor TK activity (at the Michaelis constant [K m ] for adenosine triphosphate [ATP]) was examined using an enzyme-linked immunoabsorbent assay (ELISA) with recombinant cytoplasmic domains of Src non-receptor TKs. The IC 50 concentration of AZM475271 to inhibit the phosphorylation of c-Src in HUVE and L3.6pl cells was 0.1 lmol/l (Fig. 1 a, b) .
AZM475271 inhibits tumor growth and metastasis in an orthotopic nude mouse model
To investigate the hypothesis that blockage of Src kinase function may inhibit pancreatic tumor growth, metastasis, and angiogenesis, we conducted an in vivo experiment examining the effects of AZM475271. Pancreatic tumors were allowed to become established for 7 days before initiation of treatment. The animals were sacrificed 32 days after the initiation of treatment, when >50% of the control animals had become moribund. At the time of necropsy, all control and treated mice had developed primary pancreatic tumors. The mean tumor volume was significantly decreased (~40% inhibition of primary tumor growth) in all animals treated with AZM475271. Mice who received AZM475271 had a significant reduction in the incidence of liver and lymph node metastases (Table 1 ). In addition, treatment with AZM475271 did not significantly change animal weight and daily intragastric administration of AZM475271 was well tolerated.
In vivo effect of AZM475271 on tumor cell proliferation
The immunohistochemical evaluation of cell proliferation was performed using Ki-67 staining. The mean number of Ki-67 positive tumor cells after therapy with AZM475271 was reduced over more than 50% compared to control mice. These results indicate an in vivo antiproliferative effect of AZM475271 (Fig. 2, Table 2 ).
To determine the ability of AZM475271 to induce apoptosis in pancreatic carcinoma cells TUNEL staining was carried out. Results showed a significant enhancement of apoptotic tumor cells in the AZM475271 therapy group compared to control tumors. The mean number of TUNELpositive cells was 8 ± 2 and 26 ± 11 (P < 0.05 vs. control) in control and AZM475271-treated group, respectively (Fig. 2, Table 2 ).
In vivo effect of AZM475271 on endothelial cell survival
We speculated that tumor cell apoptosis may have been due to poor perfusion after endothelial cell apoptosis. Therefore, we developed a technique with which we could evaluate endothelial cell apoptosis in vivo in tissue sections. Immunofluorescent double staining for CD31 and TUNEL showed that the number of endothelial cells undergoing apoptosis was greater in the AZM475271 group (Fig. 3) . This finding suggests that the reduced tumor size that followed therapy with Src inhibitor was not wholly a direct consequence of inhibition of tumor cell proliferation. There was a statistically significant induction of endothelial cell apoptosis in the pancreatic tumor model when AZM475271-treated tumors and control tumors were compared, suggesting that the reduction in tumor growth and metastasis in the treated group was due to endothelial cell death and not to a direct effect on the tumor cells themselves.
In vitro effect of AZM475271 in the aortic ring assay Angiogenesis was studied by culturing aortic explants in three-dimensional matrix gels (Fig. 4b) according to the procedure of Nikosia and Ottineri [33] . Endothelial cell sprouting from cultured rat aortic rings was abrogated by AZM475271 at any of the concentrations tested (1-5 lmol/ l; Fig. 4a) . At a concentration of 1 lmol/l endothelial migration and sprouting was 52% relative to untreated controls. In contrast, a concentration of 5 lmol/l inhibited sprouting by 93% relative to controls (P < 0.005 vs. control; Fig. 4a ). 
Suppression of mouse corneal neovascularization by AZM475271
The pellet sizes and the distances between the pellet and the limbus for each group were similar (data not shown), and the pellets containing sucrose aluminum sulfate alone without growth factors did not induce corneal neovascularization (Fig. 5 ). Corneal neovascularization induced by bFGF in AZM475271-treated animals was markedly reduced compared with vehicle-treated control animals (Fig. 5) . Quantitative comparison showed that all parameters relevant for measuring the extent of corneal neovascularization were significantly lower in AZM475271-treated animals. Indeed, the circumference of neovascularization and the vessel length in the corneas from AZM475271-treated mice were reduced by 34% (0.9 ± 0.5 mm vs. 2.7 ± 0.7 mm; P < 0.001) and 44% (0.58 ± 0.4 mm vs. 1.33 ± 0.3 mm; P < 0.001) respectively, compared with controls.
In vitro anti-proliferative activity of AZM475271 in L3.6pl and HUVE cells Viability assays for L3.6pl and HUVE cells were performed with the TACS MTT Cell Proliferation and Viability Assay Kit. Treatment of HUVECs with AZM475271 at high concentrations (>10 lmol/l) caused a rapid decrease in cell proliferation that could be linked to the ability of AZM475271 to induce HUVEC death, whereas a significant anti-proliferative activity of AZM475271 on HUVECs could be already observed at concentrations of 2 lmol/l or above (IC 50 = 6 lmol/l) (Fig. 6) . Interestingly, no significant inhibition of proliferation was seen on L3.6pl cells at doses up to 5 lmol/l, the anti-proliferative effect of AZM475271 on L3.6pl was seen exclusively at very high doses (IC 50 = 25 lmol/l) (Fig. 6 ). These results suggest that the anti-tumor properties of AZM475271 might predominantly be mediated through a direct effect on the endothelial cells rather that on the tumor cells.
In vitro effects of AZM475271 on VEGF and EGF dependent endothelial cell proliferation
To address the functional importance of HUVEC proliferation in response to growth factors, we treated cells with various concentrations of AZM475271 in the presence or absence of VEGF or EGF (Fig. 7) . The IC 50 concentration for AZM475271 in both VEGF-and EGF-stimulated HUVECs was significantly higher (IC 50 = 10 lmol/l; Fig. 7 ) than that found in the cells under unstimulated conditions (Fig. 6) , however, the anti-proliferative effect of Src kinase inhibitor showed at such high concentration has been a result of reduced cell numbers due to non-specific therapyinduced HUVEC death (as shown in Fig. 6 and in Fig. 9b ) and can not be linked to the inability of targeted Src being involved in the growth factor-induced cell survival pathway. Most important is that at the more physiologically relevant submicromolar doses of AZM475271 (5 and 1 lmol/l) the VEGF-and EGF-induced cell response was significantly abrogated due to target-mediated effect of AZM475271 (P < 0.001; Fig. 7 ).
Inhibition of VEGF production by L3.6pl and HUVE cells following treatment with AZM475271
The level of VEGF was measured in cell culture supernates collected on day 0, 2, and 4 from L3.6pl or HUVECs at one passage following treatment with Src kinase inhibitor at different concentrations (0.1 and 1 lmol/l).
The blockade of Src kinase by AZM475271 significantly reduced the level of VEGF in L3.6pl supernatant (Fig. 8a) , the effect which was also found in the cell culture supernate from HUVECs (Fig. 8b) . The inhibition of VEGF production by L3.6pl and HUVECs following treatment with AZM475271 was dose-dependent.
In vitro induction of cell death in HUVECs FACS analysis was used to determine the effects of AZM475271 on HUVEC cell cycle progression. Quantification of apoptosis was performed using propidium iodide staining. HUVECs were treated with AZM475271 in different concentrations for 12 h, and then cells were collected and suspended in a Nicoletti buffer. Treatment with AZM475271 resulted in the induction of apoptosis in 99% of the cells at concentrations from 10 up to 25 lmol/l as compared with 6.3% of apoptotic cells present in the untreated control (Fig. 9b) . Interestingly, at the more physiologically relevant submicromolar doses of AZM475271 (5, 1, and 0.1 lmol/l) the level of apoptotic fraction was also significantly higher (60%, 40%, and 15%, respectively) when compared with untreated cells (Fig. 9a) .
In vitro inhibition of migration of HUVECs by AZM475271
To investigate the anti-migratory effects of AZM475271 on endothelial cells we demonstrated whether Src inhibition in HUVECs prevented cell migration in a modified Boyden chamber assay. Inhibition of Src kinase resulted in a dose-depended decrease of HUVEC migration (P < 0.05; Fig. 10 ).
AZM475271 abolishes VEGF-induced FAK phosphorylation in HUVECs
Src tyrosine kinase has been shown to mediate the tyrosine phosphorylation signal from VEGFR to FAK. Focal adhesion kinase is involved in integrin-mediated signal Fig. 4 Effect of AZM475271 on rat aortic ring formation. An estimation of the length of the capillary was performed by measuring the distance from the aortic explants to the approximate mean point of capillary. Endothelial cell sprouting from cultured rat aortic rings was abrogated by AZM475271 (a) at any of the concentrations tested (1-5 lmol/l). At a concentration of 1 lmol/l endothelial migration and sprouting was 52% relative to untreated controls. By contrast, a concentration of 5 lmol/l inhibited sprouting by 93% relative to controls ( # P < 0.0004 vs. AZM475271 0 lmol/l; *P < 0.005 vs. AZM475271 0 lmol/l). Representative photographs (b) showing the in vitro anti-angiogenic activity of the Src kinase inhibitor (the rings were examined by phase contrast microscopy with a Zeiss Axiotech Vario microscope at 10· magnification, bar = 10 lm, the arrows delineate capillary outgrowth) transduction. It plays an important role in the control of several biological processes, including cell spreading, migration, and survival [36] . The recruitment of Src family kinases results in the phosphorylation of tyrosine residues 576 and 577 in the catalytic domain. Phosphorylation of tyrosines 576 and 577 is significantly elevated in the presence of c-Src in vitro and v-Src in vivo [37] . Furthermore, the maximal kinase activity of FAK immune complexes requires phosphorylation of both tyrosines 576 and 577.
Here, we test the possibility that AZM475271 could affect VEGF-induced FAK kinase activity in HUVECs. Using Western Blots, we found Src-dependent up-regulation of FAK phosphorylation. Treatment of HUVECs with AZM475271 resulted in the significant inhibition of VEGF-activated pTyr 576/577 FAK phosphorylation, indicating that VEGF mediates its effect in HUVECs at least in part via Src kinase (Fig. 11) .
Discussion
In this report, we describe a new therapeutic approach against pancreatic cancer by blockade of Src tyrosine kinase.
Currently, a large variety of chemotherapeutic drugs are being used to treat pancreatic cancer, but, unfortunately, many compounds show only limited efficacy due to problems of delivery and development of drug resistance in tumor cells. Tumor cells are rapidly changing targets because of their genetic instability, heterogeneity, and high rate of mutation, leading to selection and outgrowth of drug-resistant tumor cell populations [38, 39] .
Anti-angiogenic therapy offers several advantages over therapy directed against tumor cells. First, endothelial cells are a genetically more stable, diploid, and spontaneous mutations rarely occur. Second, the turnover of tumor endothelial cells is approximately 50 times higher than that of endothelial cells in normal quiescent tissues. Third, tumor endothelial cells as target are easily accessible by systemic administration. Finally, a high number of tumor cells is sustained by a single capillary, that means, inhibition of a small number of tumor vessels may affect the growth of many tumor cells [39] . It has been shown, that the intratumoral blood vessel density is a prognostic marker in a variety of solid tumors, including invasive breast [40] , lung [41] , malignant melanoma, gastrointestinal, [42, 43] , and genitourinary cancers [3] . The progressive growth of neoplasms also depends on the induction of angiogenesis, in these tumors a positive correlation was found between tumor angiogenesis and the risk of metastasis, tumor recurrence, and death [40] [41] [42] [43] .
Yezhelyev et al. [44] recently reported that a novel Src kinase inhibitor AZM475271, either alone or in combination with gemcitabine, demonstrated significant antitumor activity against primary tumor growth in an orthotopic nude mouse model for human pancreatic cancer. Furthermore, a decreased incidence of lymph node metastases and a complete inhibition of the liver metastases were associated with administration of Src kinase inhibitor AZM475271 monotherapy as well as combination therapy (partly mentioned by Yezhelyev et al. [44] ). These early results, which have raised questions as to the role of Src family kinases in pancreatic tumor angiogenesis and metastasis led us to extend the previous findings and to give an attention to the anti-angiogenic properties of Src kinase inhibitor AZM475271. Lutz et al. [18] examined pancreatic ductal carcinomas as well as pancreatic cell lines for elevated Src protein levels and kinase activity. Src protein levels were elevated in 13/13 pancreatic cancers and in 14/17 pancreatic cell lines. Kinase activity was only detectable in cancer cells and this activity did not correlate with either the c-Src or Csk protein levels. Furthermore, the importance of Src kinase in pancreatic cancer progression has been highlighted from some recent works [19, [45] [46] [47] .
There are several recent reports that Src contributes to the control of tumor angiogenesis. Specifically, Src is needed for hypoxia-induced vascular endothelial growth factor (VEGF) production in a number of cell types [7] . Furthermore, it has been shown, that suppression of Src in HT29 colon cancer cells by an antisense approach, led to a reduction of VEGF expression [48] . Thus, it appears that Src cannot only regulate the production of VEGF, but also control the consecutive endothelial cell response.
To investigate the hypothesis, that Src inhibitory drugs does not only affect tumor cell growth and migration, we conducted an in vivo experiments using the novel orally available Src kinase inhibitor AZM475271 in nude mice bearing human pancreatic cancer implanted orthotopically in the pancreas. The animals were sacrificed 32 days after the initiation of treatment, when >50% of the control animals had become moribund. At the time of sacrifice, all animals developed primary pancreatic tumors, however the mean tumor volume was significantly decreased (~40% inhibition of primary tumor growth) from 1,125 ± 460 mm was significantly elevated compared to control tumors (26 ± 11 vs. 8 ± 2, respectively). Moreover, double staining of endothelial cells with antibodies against CD31 and TUNEL suggested that the reduction in MVD was attributable to a significant increase of apoptosis in endothelial cells and not to a direct effect on the tumor cells themselves. This is the first report to our knowledge demonstrating that therapy with AZM475271 leads to apoptosis of endothelial cells within pancreatic tumors as determined by a double-labeling immunofluorescence procedure. The in vivo anti-angiogenic properties of AZM475271 were also demonstrated in the mouse corneal micropocket model in which neovascularization was induced by bFGF and Src kinase inhibitor was administered systemically. The results suggest that AZM475271 has a strong inhibitory effect on corneal neovascularization, the effect is explained in part by inhibition of proliferation, migration, and VEGF secretion of endothelial cells in the area of neovascularization. Moreover, the anti-angiogenic activity of the Src kinase inhibitor was also evident in vitro, where proliferation, invasion, and migration of the endothelial cells were significantly reduced by AZM475271 as well. as docking sites for the SH2 domain of Src kinase on the receptor itself or by phosphorylation of docking proteins. Once activated, Src could link VEGF-or EGF-stimulation with the PDK/PKB signaling cassette leading to stimulation of endothelial cell survival and angiogenesis [49] . However, although both growth factors stimulate Src activation, it has only been shown that VEGF-induced angiogenesis can be inhibited by treatment with a retrovirus that encodes for Src-251, a dominant-negative mutant of Src. Moreover, overexpression of Src-251 in avian blood vessels induces apoptotic death, indicating that VEGF-induced activation of Src is essential for endothelial cell survival and angiogenesis. Interestingly, VEGF-induced vascular permeability is impaired in Src -/-and in Yes -/-but not in Fyn -/-mice [25] , suggesting that the function of Src kinases in endothelial cells is not comparable to the function of other family members.
Recent reports have demonstrated a major role for Src activity in the control of cell adhesion and cytoskeletal changes, which in turn regulate cell invasion and migration [50] . To produce new vessels, endothelial cells must migrate, degrade extracellular matrix, divide, form tubes, and survive [51, 52] . Evidence is provided that VEGF activates Src kinase, which induces the phosphorylation of tyrosines 576/577 within FAK, facilitating the association of FAK with integrin a v b 3 . Integrin a v b 3 is known to bind a number of ECM proteins, among them vitronectin, fibrinogen, von Willebrand factor, fibronectin, and denatured collagen. More recent studies show that integrin a v b 3 can also bind directly to matrix metalloproteinase 2, thereby localizing the MMP-2-mediated matrix-degradation capacity to the invasive/migratory site of vascular cells during angiogenesis [53] . This enables endothelial cells to degrade and remodel the ECM during their invasion. Blockade of Src activity by AZM475271 inhibits the phosphorylation of a VEGF-induced FAK. We confirmed the antimigratory effect of AZM475271 by analysis of endothelial cell migration using a modified Boyden chamber assay revealing a strong inhibition of HUVEC migration. These findings suggest that one major role of Src activity is to cooperate with activated growth factor receptors to induce adhesion and cytoskeletal changes that are associated with invasion and metastasis. Therefore, it is possible, that Srcspecific inhibitory drugs, such as AZM475271, might primarily affect these pathways in endothelial cells, and so be useful in preventing further tumor spread, while not necessarily having such a strong influence on cancer cell growth. In summary, our study revealed that AZM475271 inhibition of Src kinase can significantly reduce the growth and metastatic potential of highly metastatic human pancreatic cancer growing in the pancreas of nude mice. Since AZM475271 is well tolerated when given to animals, therapeutic intervention aiming at inhibition of Src family kinases can be an attractive strategy in the treatment of angiogenesis-dependent diseases.
